Zimmer Biomet (NYSE: ZBH) has entered a definitive agreement to acquire Monogram Technologies (Nasdaq: MGRM) in a cash deal valued at approximately $177 million, including contingent value rights up to $12.37 per share based on future milestones.
Monogram develops semi- and fully autonomous robotic technologies designed to complement Zimmer Biomet’s flagship Rosa orthopedic robotic platform. The acquisition aims to position Zimmer Biomet as the first orthopedic company offering fully autonomous surgical robots, with plans to integrate Monogram’s technology into its portfolio.
Monogram’s mBôs system, a CT-based semi-autonomous robotic solution for total knee arthroplasty (TKA), received FDA 510(k) clearance earlier this year, with a fully autonomous version under development. Zimmer Biomet expects to commercialize these innovations alongside its existing Rosa platform, which has nearly 2,000 installations worldwide.
CEO Ivan Tornos emphasized the deal’s strategic value, aiming to provide a comprehensive robotic ecosystem tailored to surgeon preferences and advancing orthopedic surgery’s future.
Analysts noted the deal complements Zimmer Biomet’s existing offerings but raised questions about the potential impact on Rosa’s market positioning. Some view the acquisition as providing options across robotic autonomy levels, while others wonder if it signals a shift toward replacing Rosa in the long term.
The transaction is expected to close by the end of 2025, financed through cash and debt, with neutral adjusted EPS impact through 2027 and accretive effects projected thereafter.
Follow MEDWIRE.AI for orthopedic robotics and medtech mergers updates.
